Works matching IS 01676997 AND DT 2023 AND VI 41 AND IP 4

Results: 10

Idarubicin versus epirubicin in drug-eluting beads-transarterial chemoembolization for treating hepatocellular carcinoma: A real-world retrospective study.

Published in:

Investigational New Drugs, 2023, v. 41, n. 4, p. 617, doi. 10.1007/s10637-023-01377-0

By:

Zhao, Chenghao;
Yan, Huzheng;
Xiang, Zhanwang;
Wang, Haofan;
Li, Mingan;
Huang, Mingsheng

Publication type:

Article

The p53 reactivator PRIMA-1<sup>MET</sup> synergises with 5-fluorouracil to induce apoptosis in pancreatic cancer cells.

Published in:

Investigational New Drugs, 2023, v. 41, n. 4, p. 587, doi. 10.1007/s10637-023-01380-5

By:

Mohammed, Ibtehal;
Alhammer, Ali Haider;
Arif, Inam Sameh

Publication type:

Article

Safety and efficacy of immunotherapy plus chemotherapy as neoadjuvant treatment for patients with locally advanced gastric cancer: a retrospective cohort study.

Published in:

Investigational New Drugs, 2023, v. 41, n. 4, p. 579, doi. 10.1007/s10637-023-01379-y

By:

Wang, Xue;
Huang, Jinxiang;
Huang, He;
Liu, Yang;
Ji, Chao;
Liu, Jian

Publication type:

Article

Assessment of the potential of the MET inhibitor tepotinib to affect the pharmacokinetics of CYP3A4 and P-gp substrates.

Published in:

Investigational New Drugs, 2023, v. 41, n. 4, p. 596, doi. 10.1007/s10637-023-01378-z

By:

Yalkinoglu, Özkan;
Becker, Andreas;
Krebs-Brown, Axel;
Vetter, Claudia;
Lüpfert, Christian;
Perrin, Dominique;
Heuer, Jürgen;
Biedert, Herlind;
Hirt, Stefan;
Bytyqi, Afrim;
Bachmann, Angelika;
Strotmann, Rainer

Publication type:

Article

Indirect comparisons of efficacy of zanubrutinib versus orelabrutinib in patients with relapsed or refractory chronic lymphocytic leukemia/small lymphocytic lymphoma or relapsed or refractory mantle cell lymphoma.

Published in:

Investigational New Drugs, 2023, v. 41, n. 4, p. 606, doi. 10.1007/s10637-023-01376-1

By:

Song, Yuqin;
Zhou, Keshu;
Yang, Shenmiao;
Hu, Jianda;
Zou, Dehui;
Gao, Sujun;
Pan, Ling;
Wang, Tingyu;
Yang, Haiyan;
Zhang, Huilai;
Zhou, Daobin;
Ji, Jie;
Xu, Wei;
Feng, Ru;
Jin, Jie;
Lv, Fangfang;
Huang, Haiwen;
Fan, Xiaosi;
Xu, Sheng;
Zhu, Jun

Publication type:

Article

POTEE mutation as a potential predictive biomarker for immune checkpoint inhibitors in lung adenocarcinoma.

Published in:

2023

By:

Li, Yongzhao;
Yang, Qidong;
Liu, Yaqin;
Yi, Huan;
Ju, Yongzhi;
Qi, Guoyan

Publication type:

Letter

Degradation of MYC by the mutant p53 reactivator drug, COTI-2 in breast cancer cells.

Published in:

Investigational New Drugs, 2023, v. 41, n. 4, p. 541, doi. 10.1007/s10637-023-01368-1

By:

Tang, Minhong;
Crown, John;
Duffy, Michael J

Publication type:

Article

A phase I/II study of LY3022855 with BRAF/MEK inhibition in patients with Melanoma.

Published in:

Investigational New Drugs, 2023, v. 41, n. 4, p. 551, doi. 10.1007/s10637-023-01374-3

By:

Buchbinder, Elizabeth I.;
Giobbie-Hurder, Anita;
Haq, Rizwan;
Ott, Patrick A.

Publication type:

Article

Sitravatinib is a potential EGFR inhibitor and induce a new death phenotype in Glioblastoma.

Published in:

Investigational New Drugs, 2023, v. 41, n. 4, p. 564, doi. 10.1007/s10637-023-01373-4

By:

Lu, Hanwen;
Zhang, Bingchang;
Xie, Yuanyuan;
Zhao, Wenpeng;
Han, Wanhong;
Zhou, Liwei;
Wang, Zhanxiang

Publication type:

Article

Correction to: The kinesin motor protein KIF4A as a potential therapeutic target in renal cell carcinoma.

Published in:

2023

By:

Liu, Guihong;
Lu, Yachun;
Li, Liantao;
Jiang, Tao;
Chu, Sufang;
Hou, Pingfu;
Bai, Jin;
Chen, Ming

Publication type:

Correction Notice